Clinical pharmacokinetics of quinidine

Clinical Pharmacokinetics
H R OchsE Woo

Abstract

The elimination of quinidine is accomplished by a combination of renal excretion of the intact drug (15 to 40% of total clearance) and hepatic biotransformation to a variety of metabolites (60 to 85% of total clearance). Many of the metabolites appear to be pharmacologically active. Typical ranges for kinetic properites of quinidine in healthy persons are: apparent volume of distribution 2.0 to 3.5 litres/kg; elimination half-life 5 to 12 hours; clearance, 2.5 to 5.0 ml/min/kg. Quinidine clearance is reduced in the elderly, in patients with cirrhosis, and in those with congestive heart failure. Oral quinidine is available either as relatively rapidly absorbed conventional tablets (usually quinidine sulphate) or as a variety of slowly absorbed sustained release preparations. Absolute systemic availability generally is 70% or greater. Quinidine is 70 to 95% bound to plasma protein, primarily to albumin but also to a number of other plasma constituents. Binding is reduced in patients with cirrhosis, partly because of hypoalbuminaemia, but is not influenced by renal insufficiency. Clinical interpretation of total serum or plasma quinidine concentrations must be altered in patients with reduced or increased binding, since it is the ...Continue Reading

Citations

Feb 1, 1981·European Journal of Clinical Pharmacology·H R OchsR Arendt
Jul 1, 1986·European Journal of Drug Metabolism and Pharmacokinetics·P JaillonG Cheymol
Jan 1, 1983·Pharmacology & Therapeutics·D M Roden, R L Woosley
Nov 14, 1981·Lancet·N J WhiteT Harinasuta
Jul 1, 1985·Journal of the American College of Cardiology·R L GoldA M Ross
Jan 8, 1981·The New England Journal of Medicine
Jun 11, 1981·The New England Journal of Medicine·Y Twum-Barima, S G Carruthers
May 16, 1985·The New England Journal of Medicine·R E PhillipsJ Karbwang
Feb 1, 1990·British Journal of Clinical Pharmacology·K BrøsenL F Gram
Mar 1, 1990·British Journal of Clinical Pharmacology·M D NielsenL F Gram
Sep 1, 1990·British Journal of Clinical Pharmacology·T M DavisN J White
Jul 3, 2010·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Ketan HippalgaonkarSoumyajit Majumdar
Nov 4, 2008·Journal of Pharmaceutical Sciences·S GrubeD M Barends
Nov 1, 1983·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·W M BennettI Singer
Oct 4, 2011·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Makoto KataokaShinji Yamashita
Dec 1, 1987·British Journal of Clinical Pharmacology·G W MihalyR A Smallwood
Oct 1, 1983·British Journal of Clinical Pharmacology·N J WhiteK Silamut
Sep 1, 1986·British Journal of Clinical Pharmacology·S WanwimolrukP Patamasucon
Mar 1, 1987·British Journal of Clinical Pharmacology·D J EdwardsD Lalka
Aug 1, 1986·British Journal of Clinical Pharmacology·R BrinnS V Otton
Apr 1, 1985·Journal of Clinical Pharmacology·H R OchsD J Greenblatt
Aug 1, 1981·Journal of Clinical Pharmacology·D J Greenblatt, E Woo
Jun 1, 1984·British Journal of Clinical Pharmacology·A LeizoroviczS Ferry
Oct 1, 1992·Journal of Pharmacokinetics and Biopharmaceutics·M Davidian, A R Gallant
Apr 1, 1983·Biopharmaceutics & Drug Disposition·L N AceR L Kunka
Jan 1, 1989·Biopharmaceutics & Drug Disposition·J J MacKichanS F Schaal
Dec 9, 1997·Clinical Pharmacology and Therapeutics·K M KaukonenP J Neuvonen
Sep 1, 1996·Clinical Pharmacology and Therapeutics·S LaganièreI McGilveray
Aug 1, 1985·Journal of Pharmacokinetics and Biopharmaceutics·H HarashimaM Hanano
Nov 1, 1985·Drug Intelligence & Clinical Pharmacy·R M Van Lith, D H Appleby
Feb 15, 2000·British Journal of Clinical Pharmacology·P DalénL Bertilsson
Sep 1, 1982·Drug Intelligence & Clinical Pharmacy·G H Smith, R H Levy
Jan 21, 1984·The Medical Journal of Australia·G J SchapelC J Doecke

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.